Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED BALANCE SHEETS

v3.19.2
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2019
Mar. 31, 2018
Current Assets    
Cash $ 47,044 $ 60,934
Accounts receivable, net 163,405 12,386
Inventory 78,737 29,074
Prepaids and other current assets 65,273 124,455
Total Current Assets 354,459 226,849
Property and equipment, net 452,048 4,441
Equity investments 898,292 468,537
Goodwill 1,941,149
Other asset 5,500 5,500
TOTAL ASSETS 3,651,448 705,327
Current Liabilities    
Accounts payable 278,546 21,846
Note Payable 25,000
Accrued expenses 70,720 14,039
Total Current Liabilities 374,266 35,885
Commitments and Contingencies
Stockholders' Equity    
Preferred stock; $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding at March 31, 2019 and 2018
Common stock; $0.00001 par value; 200,000,000 shares authorized; 13,397,110 and 10,499,610 issued and outstanding at March 31, 2019 and 2018, respectively 135 105
Additional paid in capital 6,892,242 3,054,297
Common stock to be issued, 408,805 and 263,000 shares at March 31, 2019 and 2018, respectively 773,807 526,000
Accumulated deficit (5,531,260) (2,901,933)
Total Applied BioSciences Corp. Stockholders' Equity 2,134,924 678,469
Non-controlling interest 1,142,258 (9,027)
Total Stockholders' Equity 3,277,182 669,442
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 3,651,448 $ 705,327